Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control
Open Access
- 5 September 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (9) , 1123
Abstract
Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient’s glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.Keywords
This publication has 38 references indexed in Scilit:
- Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathyMolecular Biology Reports, 2021
- Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to CorrectionBulletin of Experimental Biology and Medicine, 2021
- Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglycerideClinica Chimica Acta, 2019
- Asprosin is a centrally acting orexigenic hormoneNature Medicine, 2017
- Asprosin, a Fasting-Induced Glucogenic Protein HormoneCell, 2016
- Parámetros de control glucémico: nuevas perspectivas en la evaluación del diabéticoMedicina Clinica, 2010
- Free radicals and antioxidants in normal physiological functions and human diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivityIndian Journal of Clinical Biochemistry, 2006
- The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP AssayAnalytical Biochemistry, 1996
- Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoproteinAnalytical Biochemistry, 1992